Market Closed -
Japan Exchange
02:00:00 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
1,969
JPY
|
+0.03%
|
|
+1.68%
|
+32.46%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
269,659
|
192,662
|
255,198
|
-
|
-
|
Enterprise Value (EV)
1 |
274,907
|
195,369
|
248,809
|
234,195
|
225,752
|
P/E ratio
|
35.7
x
|
63.5
x
|
16.2
x
|
30.6
x
|
24.1
x
|
Yield
|
-
|
-
|
-
|
0.15%
|
0.3%
|
Capitalization / Revenue
|
10
x
|
6.71
x
|
5.9
x
|
6.74
x
|
5.98
x
|
EV / Revenue
|
10.2
x
|
6.8
x
|
5.75
x
|
6.18
x
|
5.29
x
|
EV / EBITDA
|
25.1
x
|
21.2
x
|
9.31
x
|
17.9
x
|
14.6
x
|
EV / FCF
|
-72.3
x
|
17.4
x
|
11.9
x
|
22.3
x
|
17.8
x
|
FCF Yield
|
-1.38%
|
5.74%
|
8.37%
|
4.49%
|
5.62%
|
Price to Book
|
8.42
x
|
4.78
x
|
5.09
x
|
4.33
x
|
3.64
x
|
Nbr of stocks (in thousands)
|
129,831
|
129,608
|
129,608
|
-
|
-
|
Reference price
2 |
2,077
|
1,486
|
1,969
|
1,969
|
1,969
|
Announcement Date
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
26,852
|
28,712
|
43,249
|
37,877
|
42,666
|
EBITDA
1 |
10,954
|
9,206
|
26,732
|
13,117
|
15,414
|
EBIT
1 |
8,980
|
6,773
|
17,287
|
12,168
|
15,188
|
Operating Margin
|
33.44%
|
23.59%
|
39.97%
|
32.13%
|
35.6%
|
Earnings before Tax (EBT)
1 |
6,653
|
4,353
|
18,000
|
11,439
|
14,863
|
Net income
1 |
7,554
|
3,036
|
14,804
|
8,347
|
10,565
|
Net margin
|
28.13%
|
10.57%
|
34.23%
|
22.04%
|
24.76%
|
EPS
2 |
58.19
|
23.41
|
121.4
|
64.36
|
81.55
|
Free Cash Flow
1 |
-3,804
|
11,208
|
20,828
|
10,524
|
12,684
|
FCF margin
|
-14.16%
|
39.04%
|
48.16%
|
27.78%
|
29.73%
|
FCF Conversion (EBITDA)
|
-
|
121.74%
|
77.92%
|
80.23%
|
82.29%
|
FCF Conversion (Net income)
|
-
|
369.19%
|
140.7%
|
126.08%
|
120.06%
|
Dividend per Share
2 |
-
|
-
|
-
|
3.000
|
6.000
|
Announcement Date
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
419
|
4,605
|
5,024
|
6,184
|
15,644
|
-
|
4,963
|
4,463
|
9,426
|
13,118
|
6,168
|
19,286
|
4,225
|
5,610
|
10,640
|
12,940
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1,166
|
-393
|
-1,559
|
1,133
|
9,407
|
-
|
-266
|
-719.5
|
-986
|
7,739
|
20.2
|
7,759
|
-1,098
|
940
|
4,695
|
5,205
|
-
|
-
|
Operating Margin
|
-278.28%
|
-8.54%
|
-31.03%
|
18.32%
|
60.13%
|
-
|
-5.36%
|
-16.12%
|
-10.46%
|
59%
|
0.33%
|
40.23%
|
-25.99%
|
16.76%
|
44.13%
|
40.22%
|
-
|
-
|
Earnings before Tax (EBT)
|
-1,123
|
-
|
-1,484
|
1,116
|
7,022
|
-
|
-399
|
-
|
-1,110
|
5,773
|
-308.5
|
5,464
|
-1,104
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-829
|
-
|
-1,056
|
870
|
7,741
|
-
|
-248
|
-
|
-729
|
4,270
|
-505.6
|
3,765
|
-842
|
-
|
2,650
|
4,460
|
-
|
-
|
Net margin
|
-197.85%
|
-
|
-21.02%
|
14.07%
|
49.48%
|
-
|
-5%
|
-
|
-7.73%
|
32.55%
|
-8.2%
|
19.52%
|
-19.93%
|
-
|
24.91%
|
34.47%
|
-
|
-
|
EPS
2 |
-6.390
|
-
|
-8.130
|
6.690
|
59.63
|
66.32
|
-1.920
|
-3.700
|
-5.620
|
32.92
|
-3.890
|
29.03
|
-6.500
|
82.92
|
20.86
|
9.895
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/12/22
|
8/9/22
|
8/9/22
|
11/10/22
|
2/14/23
|
2/14/23
|
5/11/23
|
8/9/23
|
8/9/23
|
11/9/23
|
2/14/24
|
2/14/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
5,248
|
2,707
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
6,388
|
21,002
|
29,446
|
Leverage (Debt/EBITDA)
|
0.4791
x
|
0.294
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-3,804
|
11,208
|
20,828
|
10,524
|
12,684
|
ROE (net income / shareholders' equity)
|
26.3%
|
8.4%
|
28.4%
|
15.5%
|
17.2%
|
ROA (Net income/ Total Assets)
|
16.6%
|
6.53%
|
18.1%
|
5.5%
|
9.7%
|
Assets
1 |
45,450
|
46,493
|
81,787
|
151,756
|
108,915
|
Book Value Per Share
2 |
247.0
|
311.0
|
387.0
|
455.0
|
540.0
|
Cash Flow per Share
2 |
73.40
|
42.20
|
149.0
|
91.50
|
128.0
|
Capex
1 |
3,721
|
1,213
|
2,421
|
2,621
|
2,321
|
Capex / Sales
|
13.86%
|
4.22%
|
5.6%
|
6.92%
|
5.44%
|
Announcement Date
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
1,969
JPY Average target price
2,850
JPY Spread / Average Target +44.74% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.46% | 1.62B | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|